Multicellular living organisms and unmodified parts thereof and – Nonhuman animal – Transgenic nonhuman animal
Reexamination Certificate
2005-03-15
2005-03-15
Shukla, Ram R. (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Nonhuman animal
Transgenic nonhuman animal
C435S320100
Reexamination Certificate
active
06867348
ABSTRACT:
The present invention relates to novel promoters, including transcription regulator regions, for the mouse VEGFR-2 receptor, isolated polynucleotides comprising such promoters, nucleic acid constructs comprising such promoters operatively linked to genes encoding a gene product, such as, a reporter, a protein, polypeptide, hormone, ribozyme, or antisense RNA, recombinant cells comprising such nucleic acid constructs, screening for therapeutic drugs using such cells (e.g., screening for compounds that modulate VEGFR-2-mediated angiogenesis), and endothelial tissue-specific gene expression using these novel promoter sequences.
REFERENCES:
patent: 5650135 (1997-07-01), Contag et al.
patent: 6020121 (2000-02-01), Bao et al.
patent: 6217847 (2001-04-01), Contag et al.
patent: WO 9411499 (1994-05-01), None
patent: WO 9640979 (1996-12-01), None
patent: WO 9700957 (1997-01-01), None
patent: WO 9711690 A2 (1997-04-01), None
patent: WO 9718841 (1997-05-01), None
patent: WO 9740381 (1997-10-01), None
patent: WO 9828971 (1998-07-01), None
patent: WO 9830715 (1998-07-01), None
patent: WO 9855638 (1998-12-01), None
patent: WO 0008726 (2000-02-01), None
patent: WO 0036106 (2000-06-01), None
patent: WO 0054581 A2 (2000-09-01), None
patent: WO 0118195 (2001-03-01), None
patent: WO 0118225 (2001-03-01), None
patent: WO 0137195 (2001-05-01), None
Wood,“Phenotype Assessment: Are You Missing Something?”, Comparative Medicine vol. 50 No. 1 (2000), pp. 12-15.*
Aiello et al., “Suppresion of Retinal Neovascularization lin Vivo by Inhibition of Vascular Endothelial Growth Factor (VEGF) Using Soluble VEGF-Receptor Chimeric Proteins,”Proc. Natl. Acad. Sci. U.S.A. 92:10457-10461 (1995).
Asahara et al., “Bone Marrow Origin of Endothelial Progenitor Cells Responsible for Postnatal Vasculogenesis in Physiological and Pathological Neovascularization,”Circ. Res. 85:221-228 (1999).
Bais et al., “G-Protein-Coupled Receptor of Kaposi's Sarcoma-Associated Herpes Virus is a Viral Oncogene and Angiogenesis Activator,”Nature 391:86-89 (1998).
Benjamin et al., “Conditional Switching of Vascular Endothelial Growth Factor (VEGF) Expression in Tumors: Induction of Endothelial Cell Shedding and Regression of Hemangioblastoma-Like Vessels by VEGF Withdrawal,”Proc. Natl. Acad. Sci. U.S.A. 94:8761-8766 (1997).
Berse, B., “Vascular Permeability Factor (Vascular Endothelial Growth Factor) Gene is Expressed Differentially in Normal Tissues, Macrophases, and Tumors,”Molecular Biology of the Cell 3:211-220 (1992).
Contag et al., “Visualizing Gene Expressing Living Mammals Using a Bioluminescent Reporter,”Photochemistry and Photobiology 66(4):523-531 (1997).
Disalvo et al., “Purification and Characterization of Naturally Occurring Vascular Endothelial Growth Factor-Placenta Growth Factor Heterodimer,”The Journal of Biological Chemistry 270(13):7717-7723 (1995).
Dumont, et al., “Dominant-Negative and Targeted Null Mutations in the Endothelial Receptor Tyrosine Kinase, Tek, Reveal a Critical Role in Vasculogenesis of the Embryo,”Genes&Development 8:1897-1909 (1994).
Dvorak et al., “Distribution of Vascular Permeability Factor (Vascular Endothelial Growth Factor in Tumors: Concentration in Tumor Blood Vessels,”J. Exp. Med. 174:1275-1278 (1991).
Ferrara et al., “The Biology of Vascular Endothelial Growht Factor,”Endocr. Rev. 18(1):4-25 (1997).
Ferrara et al., “Heterozygous Embryonic Lethality Inducted by Targeted inactivation of the VEGF Gene,”Nature 380:439-442 (1996).
Fong et al., “SU5416 Is a Potent and Selective Inhibitor of the Vascular Endothelial Growth Factor Receptor (Flk-1/KDR) That Inhibits Tyrosine Kinase Catalysis, Tumor Vascularization, and Growth of Multiple Tumor Types,”Cancer Research 59:99-106 (1999).
Forsythe et al., “Activation of Vascular Endothelial Growth Factor Gene Transcription by Hypoxia-Inducible Factor 1,”Molecular and Cellular Biology 16(9):4604-4613 (1995).
Fukumura et al., “Tumor Induction of VEGF Promoter Activity in Stromal Cells,”Cell 94:715-725 (1998).
Hanahan, D., “Signaling Vascular Morphogenesis and Maintenance,”Science 277:48-50 (1997).
Ikeda et al., “Hypoxia-induced Transcriptional Activation and Increased mRNA Stability of Vascular Endothelial Growth Factor in C6 Glioma Cells,”The Journal of Biological Chemistry 270(34):19761-19765 (1995).
Jain, R.K., “Endothelial Cell Death, Augiogenesis, and Microvascular Function After Casteration in an Andgrogen-Dependent Tumor: Role of Vascular Endothelial Groth Factor,”Proc. Natl. Acad. Sci. U.S.A. 95:10820-10825 (1998).
Jeltsch et al., “Hyperplasia of Lymphatic Vessels in VEGF-C Transgenic Mice,”Science 276:1423-1425 (1997).
Kaipainen et al., “Enhanced Expression of the Tie Receptor Tyrosine Kinase Messenger RNA in the Vascular Endothelium of Metastatic Melanomas,”Cancer Research 54:6571-6577 (1994).
Kappel et al., “Identification of Vascular Endothelial Growth Factor (VEGF) Receptor-2 (Flk-1) Promother/Enhancer Sequences Sufficient for Angioblast and Endothelial Cell-Specific Transcription in Transgenic Mice,”Blood 83(12):4284-4292 (1999).
Kim et al., “Inhibition of Vascular Endothelial Growth Factor-induced Angiogenesis Suppresses Tumour Growth In Vivo,”Nature 362:841-844 (1993).
Kitsukawa et al., “Overexpression of Membrane Protein, Neuropilin, in Chimeric Mice Causes Anomalies in the Cardiovascular System, Nervous System and Limbs,”Development 121:4309-4318 (1995).
Larcher et al., “VEGF/VPF Overexpression in Skin of Transgenic Mice Induces Angiogenesis, Vascular Hyperpermeability and Accelerated Tumor Development,”Oncogene 17:303-311 (1998).
Millauer, B., “High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenes,”Cell 72:835-846 (1993).
Millauer, B., “Glioblastoma Growth Inhibited In Vivo by a Dominant-Negative Flk-1 Mutant,”Nature 367:576-579 (1994).
Millauer, B., “Dominant-Negative Inhibition of Flk-1 Suppresses the Growth of Many Tumor Types In Vivo,”Cancer Res. 56:1615-1620 (1996).
Mukhopadhyay et al., “Wild-Type p53 and v-Src Exert Opposing Influences on Human Vascular Endothelial Growth Factor Gene Expression,”Cancer Res. 15:6161-6165 (1995).
Mukhopadhyay et al., “Hypoxic Induction of Human Vascular Endothelial Growth Factor Expression Through c-Src Activation,”Nature 375:577-581 (1995).
Oh et al., “VEGF and VEGF-C: Specific Induction of Angiogenesis and Lyphangiogenesis in the Differentiated Avian Chorioallantoic Membrane,”Developmental Biology 188:96-109 (1997).
Okamoto et al., “Transgenic Mice With Increased Expression of Vascular Endothelial Growth Factor in the Retinal,”American Journal Pathology 151:281-291 (1997).
Olofason et al.,“Vascular Endothelial Growth Factor B, a Novel Growth Factor for Endothelial Cells,”Proc. Natl. Acad. Sci. U.S.A. 93:2576-2581 (1996).
Patterson et al., “Cloning and Functional Analysis of the Promoter for KDR/flk-1, a Receptor for Vascular Endothelial Growth Factor,”The Journal of Biological Chemistry 270(39):23111-23118 (1995).
Plate et al., “Vascular Endothelial Growth Factor is a Potential Tumour Angiogenesis Factor in Human Gliomas in Vivo,”Nature 359:845-848 (1992).
Plate et al, “Up-Regulation of Vascular Endothelial Growth Factor and Its Cognate Receptors in a Rat Glioma Model of Tumor Angiogenesis,”Cancer Research 53:5822-5827 (1993).
Puri et al., “The Receptor Tyrosine Kinase TIE is Required for Integrity and Survival of Vascular Endothelial Cells,”EMBO Journal 14(23):5884-5891 (1995).
Rönicke et al., “Characterization of the Endothelium-Specific Murine Vascular Endothelial Growth Factor Receptor-2 (Flk-1) Promoter,”C
Purchio Anthony F.
Zhang Ning
Robins & Pasternak LLP
Shukla Ram R.
Xenogen Corporation
LandOfFree
Methods and compositions for screening for angiogenesis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for screening for angiogenesis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for screening for angiogenesis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3385444